Fear and Avoidance in PTSD Patients (NCT04770584) | Clinical Trial Compass
RecruitingNot Applicable
Fear and Avoidance in PTSD Patients
United States300 participantsStarted 2021-09-09
Plain-language summary
The purpose of this research study is to study how the brain learns to avoid certain stimuli or situations using an experimental paradigm. The big goal is to measure brain responses and subject's feelings and expectations when they are learning to actively avoid experimental stimuli, and how fear extinction learning and monetary cost can change how and when subjects are to avoid.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
✓. SCID diagnosis consistent with no current psychiatric disorders, and no current PTSD
✓. History of trauma exposure
✓. Inclusion Criteria: Healthy controls (HC)
✓. SCID diagnosis consistent with no current psychiatric disorders ("Axis I" disorders).
Exclusion criteria
✕. History of neurologic disease (e.g. tic disorder)
✕. Current significant suicidal ideation, plan or intent or suicidal behavior in past 6 months based on CSSRS or Self-injurious behavior that involves suicidal intent, requires medical attention, or occurs daily
✕. History of seizure or significant head trauma
✕. History of the serious/significant psychiatric diagnosis ("Axis I" disorders)
✕. Use of neuroleptics within one year prior to study
✕. Current substance use (assessed by urine toxicology; positive urine toxicology screen for any substance, with the exception of THC). Per PI judgement and approval: if urine toxicology is positive for a substance, participant may be eligible to proceed with study provided their urine toxicology (or saliva test for THC) is negative at experimental visit(s)
What they're measuring
1
Skin Conductance Response (SCR)
Timeframe: Experimental Day 1, Experimental Day 2
2
Functional MRI (fMRI) responses
Timeframe: Experimental Day 1, Experimental Day 2
Trial details
NCT IDNCT04770584
SponsorThe University of Texas Health Science Center, Houston